Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | THRA | P10827 | 4/20 | 0.36 |
| ▸ | THRB | P10828 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KLK1 | P06870 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12260209 | 0.91 | ALDH1A1 (0.40) | ALDH1A1MEN1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL9945985 | 0.83 | ALDH1A1 (0.40) | ALDH1A1MEN1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL16687424 | 0.83 | THRA (0.47) | ALDH1A1MEN1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL3313015 | 0.78 | THRB (0.42) | ALDH1A1MEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL9946006 | 0.76 | THRA (0.46) | ALDH1A1MEN1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL257830 | 0.76 | MEN1 (0.40) | ALDH1A1MEN1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL12269067 | 0.76 | ALDH1A1 (0.40) | ALDH1A1MEN1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL9945937 | 0.75 | LMNA (0.32) | — | |
| SCHEMBL13429874 | 0.74 | ALDH1A1 (0.39) | ALDH1A1MEN1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL3319730 | 0.73 | ALDH1A1 (0.41) | ALDH1A1MEN1KMT2ASMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | ALDH1A1 4010/4885MEN1 4590/4885KMT2A 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.